CapitolRadar tracks every publicly disclosed ASND trade by US congress members and corporate insiders: 0 disclosed trades (0 buys, 0 sells) by 0 tracked traders. Updated daily from official filings.
Want a ping when Congress buys ASND? Free email alerts on notable disclosed trades — plus a $100,000 fantasy portfolio to play along against three AI traders. Join free
Ascendis Pharma A/S (ASND) — Healthcare · Biotechnology, market cap about $14.2B.
CapitolRadar signal history
NEW PICK 2026-09-28
Ascendis Pharma director Jean Jacques Bienaime disclosed a roughly $2.29 million ASND stock purchase. The panel passed mainly because he has no verified trading track record, so the large purchase remains an unproven signal. A record of prior purchases outperforming SPY, ideally supported by recent buying from other insiders, would have strengthened the case; the 167-day disclosure delay also makes the information less timely.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with …
Frequently asked questions
How current is this page?
It re-renders from the tracked record on every view and new filings are ingested daily — but STOCK Act disclosures can lag the trade by up to 45 days, so the most recent weeks are always incomplete.
Get alerts when trades like these are disclosed. Free account: fantasy portfolio + email alerts. Premium: a 6-hour head start on every signal.
CapitolRadar tracks publicly disclosed trades (STOCK Act filings and SEC Form 4). Disclosures can lag the trade by up to 45 days. Backtests measure past disclosed buys against the S&P 500 and do not predict future results. Everything on this page is impersonal information for your own research — not investment advice.